Loading clinical trials...
Loading clinical trials...
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistan...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Progenics Pharmaceuticals, Inc.
NCT06274047 · Androgen Axis Suppression, Prostatectomy, and more
NCT07226986 · PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
NCT07436078 · Female Breast Cancer, Prostate Cancer, and more
NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more
NCT06922318 · Metastatic Castration-resistant Prostate Cancer
Progenics Pharmaceuticals, Inc.
Tarrytown, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions